Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15951066rdf:typepubmed:Citationlld:pubmed
pubmed-article:15951066lifeskim:mentionsumls-concept:C0030393lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C0026438lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C1657306lld:lifeskim
pubmed-article:15951066lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:15951066pubmed:issue38lld:pubmed
pubmed-article:15951066pubmed:dateCreated2005-8-15lld:pubmed
pubmed-article:15951066pubmed:abstractTextA set of recombinant, live attenuated human parainfluenza virus type 1 (rHPIV1) vaccine candidates was evaluated for attenuation, immunogenicity, and protective efficacy in African green monkeys (AGMs). Temperature sensitive (ts) and non-ts attenuating (att) mutations in the P/C and L genes were introduced individually or in various combinations into rHPIV1, including the C(R84G) and HN(T553A) mutations identified in the present work and the C(F170S), L(Y942A), and L(L992C) mutations identified previously. The rHPIV1 vaccine candidates exhibited a spectrum of attenuation in AGMs. One genetically and phenotypically stable vaccine candidate, rC(R84G/F170S)L(Y942A/L992C), was attenuated and efficacious in AGMs and is a promising live attenuated intranasal HPIV1 vaccine candidate suitable for clinical evaluation.lld:pubmed
pubmed-article:15951066pubmed:languageenglld:pubmed
pubmed-article:15951066pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15951066pubmed:citationSubsetIMlld:pubmed
pubmed-article:15951066pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15951066pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15951066pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15951066pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15951066pubmed:statusMEDLINElld:pubmed
pubmed-article:15951066pubmed:monthSeplld:pubmed
pubmed-article:15951066pubmed:issn0264-410Xlld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:MurphyBrian...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:CollinsPeter...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:SkiadopoulosM...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:SurmanSonja...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:NewmanJason...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:BartlettEmmal...lld:pubmed
pubmed-article:15951066pubmed:authorpubmed-author:Amaro-Carambo...lld:pubmed
pubmed-article:15951066pubmed:issnTypePrintlld:pubmed
pubmed-article:15951066pubmed:day7lld:pubmed
pubmed-article:15951066pubmed:volume23lld:pubmed
pubmed-article:15951066pubmed:ownerNLMlld:pubmed
pubmed-article:15951066pubmed:authorsCompleteYlld:pubmed
pubmed-article:15951066pubmed:pagination4631-46lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:meshHeadingpubmed-meshheading:15951066...lld:pubmed
pubmed-article:15951066pubmed:year2005lld:pubmed
pubmed-article:15951066pubmed:articleTitleHuman parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.lld:pubmed
pubmed-article:15951066pubmed:affiliationLaboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6511, 50 South Drive MSC 8007, Bethesda, MD 20892-8007, USA. EBartlett@niaid.nih.govlld:pubmed
pubmed-article:15951066pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15951066lld:pubmed